MeSH term
Frequency | Condition_Probility | Adolescent | 35 | 0.0 |
Child | 32 | 0.0 |
*Circadian Rhythm | 2 | 0.0 |
Eosinophil-Derived Neurotoxin | 63 | 77.0 |
Female | 63 | 0.0 |
Forced Expiratory Volume | 8 | 8.0 |
Humans | 107 | 0.0 |
Male | 66 | 0.0 |
Research Support, Non-U.S. Gov't | 53 | 0.0 |
Ribonucleases/*urine | 3 | 100.0 |
Animals | 15 | 0.0 |
Biological Markers | 7 | 0.0 |
Blood Proteins/*analysis | 17 | 11.0 |
Cohort Studies | 3 | 0.0 |
Comparative Study | 15 | 0.0 |
Dust/adverse effects | 2 | 25.0 |
Eosinophil Granule Proteins | 71 | 32.0 |
Immunoglobulin E/blood | 7 | 5.0 |
Infant | 6 | 0.0 |
Leukotriene E4/*urine | 3 | 100.0 |
Mites | 2 | 20.0 |
Nasal Lavage Fluid/*chemistry | 4 | 50.0 |
Ribonucleases/*analysis | 4 | 100.0 |
Allergens/*adverse effects | 2 | 18.0 |
Case-Control Studies | 4 | 0.0 |
Inflammation | 3 | 0.0 |
Leukocyte Count | 18 | 1.0 |
Nasal Provocation Tests | 3 | 23.0 |
Adult | 38 | 0.0 |
Blood Proteins/analysis | 12 | 7.0 |
Middle Aged | 30 | 0.0 |
Aged | 20 | 0.0 |
Asthma/drug therapy/metabolism/*pathology/physiopathology | 2 | 100.0 |
*Breath Tests | 2 | 16.0 |
Nitric Oxide/*analysis | 3 | 30.0 |
Administration, Topical | 3 | 2.0 |
Glucocorticoids | 4 | 13.0 |
*Ribonucleases | 63 | 30.0 |
Severity of Illness Index | 5 | 0.0 |
Single-Blind Method | 2 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Eosinophil Peroxidase | 13 | 22.0 |
Peroxidase/*analysis | 3 | 15.0 |
Peroxidases/*analysis | 2 | 18.0 |
Sputum/*chemistry | 2 | 16.0 |
Analysis of Variance | 2 | 0.0 |
Biological Markers/urine | 3 | 4.0 |
Child, Preschool | 10 | 0.0 |
Eosinophils/*physiology | 10 | 23.0 |
Longitudinal Studies | 3 | 0.0 |
Prospective Studies | 3 | 0.0 |
Respiratory Function Tests | 4 | 2.0 |
Blood Proteins/*metabolism | 5 | 2.0 |
Eosinophils/chemistry | 2 | 40.0 |
Infant, Newborn/*immunology | 2 | 8.0 |
Allergens/immunology | 4 | 5.0 |
Asthma/immunology/*urine | 2 | 100.0 |
Blood Proteins/*urine | 6 | 85.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Radioimmunoassay | 4 | 0.0 |
Statistics, Nonparametric | 3 | 0.0 |
Administration, Inhalation | 3 | 1.0 |
Cross-Over Studies | 2 | 0.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Double-Blind Method | 4 | 0.0 |
Exercise Test | 2 | 0.0 |
Skin Tests | 5 | 2.0 |
Pollen/immunology | 3 | 9.0 |
Trees/immunology | 2 | 66.0 |
Blood Proteins/metabolism | 7 | 3.0 |
Eosinophils/*metabolism | 6 | 18.0 |
Ribonucleases/metabolism | 3 | 2.0 |
English Abstract | 8 | 0.0 |
Asthma/blood/*immunology/urine | 2 | 100.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 2 | 1.0 |
Eosinophils/*immunology | 5 | 8.0 |
Sensitivity and Specificity | 2 | 0.0 |
Blood Proteins/analysis/urine | 2 | 100.0 |
Peroxidases/*genetics | 2 | 18.0 |
Combined Modality Therapy | 2 | 0.0 |
Mites/immunology | 2 | 5.0 |
Neutrophils/physiology | 3 | 2.0 |
Peroxidase/blood | 4 | 8.0 |
Seasons | 3 | 2.0 |
Logistic Models | 2 | 0.0 |
Lymphocytes/cytology | 2 | 2.0 |
Receptors, Interleukin-2/blood | 2 | 2.0 |
Feces/chemistry | 2 | 4.0 |
Inflammation Mediators/analysis | 6 | 25.0 |
Feces/*chemistry | 3 | 11.0 |
Inflammation Mediators/*analysis | 5 | 19.0 |
alpha 1-Antitrypsin/analysis | 2 | 2.0 |
Biological Markers/analysis | 4 | 0.0 |
*Eosinophils/immunology | 2 | 66.0 |
Anti-Inflammatory Agents/therapeutic use | 4 | 4.0 |
Chemiluminescent Measurements | 2 | 1.0 |
Peroxidases/analysis | 3 | 33.0 |
Bronchi/pathology | 2 | 10.0 |
Biological Markers/blood/urine | 2 | 4.0 |
Bronchial Provocation Tests | 5 | 6.0 |
Eosinophils | 7 | 18.0 |
Glycoproteins/analysis | 2 | 3.0 |
Leukotriene E4/urine | 2 | 50.0 |
Peroxidase/analysis | 4 | 6.0 |
Inflammation Mediators/*metabolism | 3 | 5.0 |
Peroxidases/metabolism | 3 | 12.0 |
In Vitro | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Irrigation | 2 | 3.0 |
Time Factors | 5 | 0.0 |
Acute Disease | 2 | 0.0 |
Biological Markers/*analysis | 2 | 1.0 |
Blood Proteins/urine | 2 | 100.0 |
Hypereosinophilic Syndrome/*blood | 2 | 100.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
Inflammation Mediators/metabolism | 3 | 4.0 |
Inflammation Mediators/*blood | 2 | 4.0 |
Tissue Distribution | 2 | 0.0 |
Asthma/*metabolism | 3 | 13.0 |
Peroxidase/metabolism | 2 | 1.0 |
Interleukin-6/analysis | 2 | 2.0 |
*Cell Degranulation | 3 | 20.0 |
Cells, Cultured | 2 | 0.0 |
Interleukin-5/*pharmacology | 2 | 6.0 |
Peak Expiratory Flow Rate | 3 | 25.0 |
Blood Specimen Collection | 2 | 4.0 |
Mice | 3 | 0.0 |
Inflammatory Bowel Diseases/*metabolism | 2 | 15.0 |
Antigens, Dermatophagoides | 3 | 5.0 |
Microscopy, Electron | 2 | 0.0 |
Allergens | 2 | 11.0 |
Glycoproteins/immunology | 2 | 2.0 |
Granulocytes/*immunology | 2 | 5.0 |
Serine Endopeptidases/blood | 2 | 25.0 |
*Electrocardiography | 2 | 3.0 |
Reference Values | 2 | 0.0 |
Electrocardiography/*methods | 2 | 11.0 |
Reproducibility of Results | 2 | 0.0 |
*Signal Processing, Computer-Assisted | 2 | 6.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 2 | 0.0 |
Antigens, CD11b/immunology | 2 | 33.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Inflammation Mediators/*blood/*urine | 2 | 100.0 |
*Oncogene Proteins | 2 | 3.0 |
Flow Cytometry | 2 | 0.0 |
